Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives $29.00 Consensus Target Price from Brokerages

Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Free Report) have earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have covered the stock in the last year is $29.00.

A number of brokerages have recently weighed in on ALPN. Wolfe Research began coverage on shares of Alpine Immune Sciences in a report on Thursday, February 15th. They issued an “outperform” rating and a $44.00 price objective on the stock. Wedbush raised their price objective on shares of Alpine Immune Sciences from $26.00 to $35.00 and gave the company an “outperform” rating in a report on Friday, January 26th. Finally, HC Wainwright raised their price objective on shares of Alpine Immune Sciences from $17.00 to $32.00 and gave the company a “buy” rating in a report on Friday, December 22nd.

Get Our Latest Stock Analysis on ALPN

Insiders Place Their Bets

In other Alpine Immune Sciences news, CEO Mitchell Gold sold 41,063 shares of Alpine Immune Sciences stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $17.32, for a total value of $711,211.16. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Alpine Immune Sciences news, insider James Paul Rickey sold 11,600 shares of Alpine Immune Sciences stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $19.00, for a total value of $220,400.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Mitchell Gold sold 41,063 shares of Alpine Immune Sciences stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $17.32, for a total transaction of $711,211.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 305,997 shares of company stock valued at $6,007,175. Insiders own 42.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its stake in shares of Alpine Immune Sciences by 745.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,312 shares during the period. Royal Bank of Canada increased its stake in shares of Alpine Immune Sciences by 99.1% during the second quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 1,315 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Alpine Immune Sciences during the fourth quarter worth about $58,000. AJOVista LLC acquired a new position in shares of Alpine Immune Sciences during the fourth quarter worth about $64,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Alpine Immune Sciences during the third quarter worth about $35,000. 75.17% of the stock is currently owned by institutional investors and hedge funds.

Alpine Immune Sciences Trading Down 2.9 %

Shares of ALPN opened at $35.93 on Friday. Alpine Immune Sciences has a twelve month low of $6.39 and a twelve month high of $39.27. The firm’s fifty day simple moving average is $26.80 and its 200-day simple moving average is $18.11. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of -29.94 and a beta of 1.13.

Alpine Immune Sciences Company Profile

(Get Free Report

Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.

Featured Articles

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.